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Abstract
Human androgen receptor (AR) transcriptional activity involves interdomain and coactivator
interactions with the agonist-bound AR ligand binding domain (LBD). Structural determinants of
the AR NH2- and carboxyl-terminal interaction between the AR NH2-terminal FXXLF motif and
activation function 2 (AF2) in the LBD were shown previously by crystallography. In this report,
we provide evidence for a region in AR LBD helix 12 outside the AF2 binding cleft that facilitates
interactions with the FXXLF and LXXLL motifs. Mutagenesis of glutamine 902 to alanine in AR
LBD helix 12 (Q902A) disrupted AR FXXLF motif binding to AF2, but enhanced coactivator
LXXLL motif binding. Functional compensation for defective FXXLF motif binding by AR-
Q902A was suggested by the slower dissociation rate of bound androgen. Functional importance
of glutamine 902 was indicated by the charged residue germline mutation Q902R that caused
partial androgen insensitivity, and a similar somatic mutation Q902K reported in prostate cancer,
both of which increased the androgen dissociation rate and decreased AR transcriptional activity.
High affinity equilibrium androgen binding was retained by alanine substitution mutations at
Tyr-739 in AR LBD helix 5 or Lys-905 in helix 12 structurally adjacent to AF2, whereas
transcriptional activity decreased and the androgen dissociation increased. Deleterious effects of
these loss of function mutations were rescued by the helix stabilizing AR prostate cancer somatic
mutation H874Y. Sequence NH2-terminal to the AR FXXLF motif contributed to the AR NH2-
and carboxyl-terminal interaction based on greater AR-2-30 FXXLF motif peptide binding to the
agonist-bound AR LBD than a shorter AR-20-30 FXXLF motif peptide. We conclude that helix 12
residues outside the AF2 binding cleft modulate AR transcriptional activity by providing
flexibility to accommodate FXXLF or LXXLL motif binding.
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The androgen receptor (AR) is a ligand-dependent transcription factor that regulates
androgen-dependent gene transcription by binding androgen response element DNA and
interacting with coregulatory proteins and transcription factors. AR transcriptional activity
requires the unstructured NH2-terminal activation function 1 (Simental et al., 1991; Lavery
et al., 2008) and the highly structured ligand binding domain (LBD) that includes the
activation function 2 (AF2) hydrophobic surface for FXXLF or LXXLL motif binding (He et
al., 2004). Structural stability and function of AF2 depends on AR binding of testosterone,
dihydrotestosterone (DHT) or synthetic anabolic steroids (Wilson, 2007). Transcriptional
activity from activation function 1 and AF2 is regulated by the androgen-dependent NH2-
and carboxyl-terminal (N/C) interaction between the NH2-terminal FXXLF motif and AF2
that has been extensively characterized for AR (Langley et al., 1995; He and Wilson, 2002;
Wilson, 2009). An N/C interaction was also reported for the estrogen (Kraus et al., 1995),
progesterone (Tetel et al., 1999) and mineralocorticoid receptors (Pippal et al., 2009),
although the interaction motifs were not defined. The androgen-dependent AR N/C
interaction is inhibited by the classical AR antagonists, hydroxyflutamide and casodex
(Langley et al., 1995; Wilson, 2011). Similarly, the mineralocorticoid receptor N/C
interaction is induced by aldosterone or the synthetic agonist 9α-fludrocortisol, and is
inhibited by deoxycorticosterone, cortisol (Pippal et al., 2009) or synthetic mineralocorticoid
receptor antagonists (Murai-Takeda et al., 2010).
The AR N/C interaction mediates an intermolecular interaction (Langley et al., 1995, 1998;
Schaufele et al., 2005) that is influenced by coregulatory proteins. AR regulation of
androgen-dependent genes that depend on the AR N/C interaction is enhanced by p160
coactivators, such as transcriptional intermediary factor 2 (TIF2). Other AR coactivators
compete with the AR N/C interaction by binding AF2 through their own FXXLF (He et al.,
2002b; Hsu et al., 2003) or FXXLF-related motif (van de Wijngaart et al., 2006). The AR
coregulator melanoma antigen-A11 (MAGE-11) binds the AR FXXLF motif in a
competitive relationship with the N/C interaction (Bai et al., 2005) and increases AR
transcriptional activity by exposing AF2 for coactivator recruitment and by interacting
directly with p160 and p300 coactivators (Askew et al., 2009, 2010). MAGE-11 is a
primate-specific steroid receptor coregulator that undergoes post-translational modulation by
phosphorylation and monoubiquitinylation (Bai and Wilson, 2008), colocalizes with AR in
nuclei of cells in the human male and female reproductive tracts (Bai et al., 2008), and is
overexpressed in castration-recurrent prostate cancer (Karpf et al., 2009; Wilson, 2010). AR
transcriptional activity mediated by the N/C interaction was reported to be enhanced by
peroxisome proliferator-activated receptor γ-coactivator-1α (Shiota et al., 2010), c-Jun
(Bubulya et al, 2001), CBP and F-SRC-1 (Ikonen et al., 1997). Inhibition of AR
transcriptional activity by interference with the AR N/C interaction has been attributed to
PTEN-FoxO1 (Ma et al., 2009), p53 (Shenk et al., 2001), cyclin D1 (Burd et al., 2004) and
AR corepressors.
The androgen insensitivity syndrome (AIS) is associated with partial or complete absence of
male sex development caused by single amino acid mutations in the AR gene, demonstrating
the functional importance of AR in male sex development and function (Quigley et al.,
1995). Loss of function AR mutations that cause AIS can disrupt androgen binding or AR
binding to androgen response element DNA. However, some naturally occurring AR
mutants retain high affinity androgen binding and cause AIS or oligospermic infertility by
interfering with the AR N/C interaction (Langley et al., 1998; He et al., 1999, 2006;
Jääskeläinen et al., 2006; Ghali et al., 2003; Thompson et al., 2001; Ghadessy et al., 1999;
Quigley et al., 2004). Loss of function AR mutations highlight the physiological importance
of the N/C interaction in AR function. Conversely, gain of function AR mutations that occur
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with low frequency in prostate cancer may contribute to castration-recurrent growth by
enhancing the AR N/C interaction (Tan et al, 1997; He et al., 2006; Askew et al., 2007). In
this report, we provide biochemical evidence that AR LBD surface residues Gln-902,
Tyr-739 and Lys-905 structurally adjacent to AF2 facilitate FXXLF or LXXLL motif
binding.
2. Material and methods
2.1. Plasmids
Human AR expression vector pCMV-AR (Lubahn et al., 1988) and H874Y (Tan et al.,
1997; He et al., 2006) and I737T mutants (He et al., 1999; Quigley et al., 2004), pCMV-
AR-507-919 (Simental et al., 1991) and H874Y mutant (He et al., 2006), GAL-AR-658-919
and H874Y mutant (Askew et al., 2007), GAL-AR-20-30 FXXLF motif fusion peptide (He
and Wilson, 2003), pNLVP16-AR-1-660 (Langley et al., 1998), VP-TIF2.1 (VP-
TIF2-624-1287) (Voegel et al., 1998; He et al., 1999), and PSAEnh-Luc and 5XGAL4Luc3
reporter vectors (Askew et al., 2010) were described. pCMV-AR-Q902A, Q902R, Q902K
and Y739A were created by double PCR mutagenesis and subcloning into TthIII and XbaI
sites of pCMV-AR. pCMV-AR-K905A was created by double PCR mutagenesis and
subcloning the amplified fragments into the Csp45I and XbaI sites of pCMV-AR. pCMV-
AR-H874Y,Y739A and H874Y,I737T were created by subcloning KpnI and Csp45I
fragment of pCMV-AR-Y739A or pCMV5 AR-I737T into pCMV-AR-H874Y. pCMV-AR-
H874Y,K905A was created by double PCR mutagenesis of pCMV-H874Y and subcloning
the Csp45I and XbaI fragments into pCMV-H874Y. pCMV-AR-507-919-Q902A, Q902K
and Q902R were created by excising the BglII and KpnI fragments from pCMVAR mutants
and self-ligating the plasmids, with translation initiation beginning at AR Met-507.
GALAR-658-919-Q902A, Y739A and K905A were created by digesting pCMV-AR mutant
plasmids with TthIII and XbaI and subcloning the fragments into GALO digested with the
same enzymes to express a fusion protein with GAL4 DNA binding domain residues 1-147
(Finkel et al., 1993). The extended GAL-AR-2-30 FXXLF motif fusion peptide was created
by PCR amplifying pCMV-AR and subcloning the fragment into EcoRI and BamHI sites of
GALO. All PCR amplified regions were verified by DNA sequencing.
2.2. AR transcription assays
Monkey kidney CV1 cells (4 × 105/6 cm dish) were transfected using calcium phosphate
precipitation (He et al., 2001). Human cervical carcinoma HeLa cells (5 × 104 cells/well) in
12 well plates were transfected using FuGENE 6 (Askew et al., 2007). After 24 h incubation
at 37°C in serum-free medium with or without hormone, cells were lysed in 0.5 ml (CV1
cells) or 0.25 ml (HeLa cells) buffer containing 1% Triton X-100, 2 mM EDTA and 25 mM
Tris phosphate, pH 7.8. After rocking for 30 min at room temperature, 0.1 ml of cell lysates
were analyzed for luciferase activity using a LumistarGalaxy BMG Labtech luminometer.
Data shown are the mean and standard error representative of 3 or more independent
experiments.
2.3. Ligand binding, dissociation and immunoblot analysis
Androgen dissociation rate studies were performed in whole cell binding assays using 3 nM
[1,2,4,5,6,7-3H]-DHT (124 Ci/mmol), 5 nM [1,2,6,7-3H]-testosterone (78.5 Ci/mmol) or 5
nM [3H]-17α-methytrienolone (R1881) (82 Ci/mmol) (PerkinElmer). COS cells (4 × 105/
well) in 6 well plates were transfected using DEAE-dextran with 1 µg/well wild-type or
mutant pCMV-AR or 2 µg/well wild-type or mutant pCMV-AR-507-919 that expresses the
human AR DNA binding domain and LBD (He et al., 2001, 2006; Askew et al., 2007). After
a 2 h incubation at 37°C, ligand dissociation was initiated by the addition of a 10,000-fold
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excess of unlabeled testosterone or R1881. Cells were solubilized in SDS sample buffer and
analyzed by scintillation counting.
Equilibrium androgen binding constants were determined in COS cell binding assays by
Scatchard plot analysis. COS cells (2 × 105/well) in 12 well plates were transfected using
DEAE dextran with 0.05 µg wild-type or mutant pCMV-AR/well. The next day cells were
incubated with 0.2 up to 6 nM [3H]R1881 for 2 h at 37°C in the absence and presence of a
100-fold molar excess of unlabeled R1881 to account for nonspecific binding (He et al.,
2006).
Immunoblots were performed using COS cells (2.5 × 106/10 cm dish) transfected with 5–10
µg DNA using DEAE dextran (He et al., 2001). The next day cells were transferred to
serum-free media, and 24 h later harvested in lysis buffer containing 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride
and complete protein inhibitor mixture (Roche Applied Science). In some experiments, 1
µM MG132 proteosome inhibitor was added 24 h and again 1 h prior to cell harvest to
stabilize the peptides and fragments. Transfer blots were probed using rabbit polyclonal anti-
GAL antibody (Santa Cruz Biotechnology, 1:200 dilution), AR52 antipeptide antibody (5
µg/ml) (Lubahn et al., 1988), AR32 antipeptide antibody (0.4 µg/ml) (Quarmby et al., 1990)
and mouse β-actin antibody (Abcam, 1:5000 dilution). Immunodetection utilized
chemiluminescence with SuperSignal West Dura Extended Duration Substrate (Pierce).
2.4. Crystallization of AR LBD bound to AR-2-30 peptide and testosterone
Wild-type AR-663-919 with an NH2-terminal 6 residue histidine tag and thrombin cleavage
site was expressed in Escherichia coli and cocrystalized with the AR-2-30 FXXLF motif
peptide in the presence of testosterone as described (Askew et al., 2007). High resolution
structure indicated identical contact sites in the AR AF2 hydrophobic surface for this longer
α-helical AR-2-30 FXXLF motif peptide as a shorter AR-20-30 FXXLF motif peptide
(Askew et al., 2007), with no electron density for the 2–19 amino acid residue region of the
AR-2-30 FXXLF motif bound peptide.
3. Results
3.1. Inhibition of AR transcriptional activity by charged residue substitutions at AR LBD
helix 12 Gln-902
The AR-Q902K germline mutation causes partial androgen insensitivity (Umar et al., 2005),
whereas AR-Q902R was reported as a somatic mutation in castration-recurrent prostate
cancer (Taplin et al., 1995). Both of these AR LBD helix 12 mutations of Gln-902 decreased
the androgen-dependent AR N/C interaction in mammalian two hybrid assays between the
GAL-AR-658-919 fusion protein of the GAL4 DNA binding domain and human AR LBD,
and the VP-AR-1-660 fusion protein of the VP16 activation domain and human AR NH2-
terminal and DNA binding domains (Fig. 1A, left). Disruption of the N/C interaction and
AR transcriptional activity caused by mutations in the AR NH2-terminal FXXLF motif have
demonstrated the functional requirement for the androgen-dependent AR N/C interaction
(He et al., 2000). AR mutations Q902K and Q902R in GAL-AR-658-919 also inhibited the
interaction with VP-TIF2-624-1287, a VP16 activation domain fusion protein with the 3
LXXLL motif region of the p160 coactivator, TIF2 (Fig. 1A, right). The decreased
interaction of these mutants did not result from differences in expression assayed in COS
cells after incubation with MG132, a proteosome inhibitor used to stabilize the fragments
(Fig. 1A, inset).
Full-length AR-Q902K and AR-Q902R were also expressed at similar levels to wild-type
AR (Fig. 2A), but were transcriptionally less active in the presence of increasing
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concentrations of DHT (Fig. 2B) or testosterone (Fig. 2C) using the prostate-specific antigen
reporter gene that depends on the AR N/C interaction for full activity (He et al., 2002a). The
Q902K and Q902R mutations increased the dissociation rate of DHT, testosterone and
R1881 up to 4 fold from full-length AR (Table 1, top panel), and from the carboxyl-terminal
AR-507-919 DNA binding domain and LBD fragment (Table 1, lower panel). AR-Q902K
equilibrium binding affinity for [3H]R1881 was elevated as reported (Umar et al., 2005),
whereas AR-Q902R equilibrium binding affinity was similar to wild-type AR (Table 1, top
panel). The increased rates of androgen dissociation from AR-507-919-Q902K and -Q902R
suggested structural defects by the mutations in the ligand binding pocket.
3.2. Gln-902 facilitates FXXLF over LXXLL motif binding
A decrease in AR FXXLF motif binding in the N/C interaction was also seen with GAL-
AR-658-919-Q902A, in which Gln-902 was replaced by nonpolar alanine (Fig. 1A, left).
However, unlike the charged residue substitution mutations Q902K and Q902R, Q902A
increased GAL-AR-658-919 binding to the TIF2 LXXLL motif fragment. Selective loss of
AR FXXLF motif binding by AR-Q902A was observed over a 4 log dose response range of
DHT (Fig. 1B) or testosterone (not shown), whereas TIF2 LXXLL motif binding increased
(Fig. 1A and 1B). The AR-H874Y prostate cancer somatic mutation (Tan et al., 1997) that
stabilizes AR LBD helix interactions (Askew et al., 2007) retained FXXLF and LXXLL
motif binding in the presence of DHT similar to wild-type AR (Fig. 1B).
Unlike the charged residue substitutions at Gln-902 associated with AIS and prostate cancer,
transcriptional activity of AR-Q902A and AR-H874Y mutants, which were expressed at
similar levels to wild-type AR (Fig. 2A), was similar to wild-type AR in the presence of
DHT (Fig. 2B), but greater than wild-type AR with testosterone (Fig. 2C). Dissociation of
testosterone, DHT or R1881 from full-length AR-Q902A was similar to wild-type, although
the equilibrium binding constant for [3H]R1881 increased (Table 1). Dissociation rates of
DHT and R1881 from AR-507-919-Q902A were almost 2 fold slower than from the wild-
type fragment, with no change with testosterone.
Disruption of AR FXXLF motif binding by AR AF2 site mutants that retain high affinity
equilibrium androgen binding has been shown to increase the rate of androgen dissociation
(Langley et al., 1998; He et al., 2000, 2001). The increased transcriptional activity of AR-
Q902A with testosterone and slower dissociation of bound androgen from the AR-Q902A
LBD fragment (Table 1) (Askew et al., 2007) suggested that the Q902A mutation stabilizes
the LBD and rescues structural defects associated with impaired AR FXXLF motif binding.
3.3. Dependence of AR transcriptional activity on AF2 flanking surface
The structural requirements for FXXLF or LXXLL motif binding to AF2 were investigated
further based on the proximity of AR LBD helix 5 Tyr-739 and helix 12 Lys-905 to Gln-902
in helix 12 (Fig. 3), and evidence that AR-Y739D caused complete AIS (Suzuki et al.,
2001). Similar to Q902A, the Y739A and K905A mutations disrupted AR FXXLF motif
binding to a greater extent than binding to the TIF2 LXXLL motifs (Fig. 1C). However,
although AR-Y739A and K905A were expressed at levels similar to wild-type AR (Fig. 2A)
and retained high affinity equilibrium binding of [3H]R1881 (Table 1), transcriptional
activity by these mutants was less than wild-type AR in the presence of DHT (Fig. 2B) or
testosterone (Fig. 2C). In addition, androgen dissociation rates were 2 to 4 fold faster for
DHT, testosterone and R1881 from full-length AR and the AR-507-919 mutants (Table 1) as
observed for ARQ902R and Q902K (Fig. 2B, 2C, Table 1). The results suggest that the
extended region of helix 12 outside the AF2 binding cleft participates in AR FXXLF and
coactivator LXXLL motif binding required for full AR transcriptional activity.
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3.4. Compensatory effects of LBD stabilization
The increased transcriptional activity of AR-Q902A and AR-H874Y, together with the
slower androgen dissociation rates, suggested that stabilization of the LBD core can
overcome the detrimental effects of destabilizing mutations. To investigate this further,
chimeras were created between a loss of function mutation in or near helix 12 and the AR
helix stabilizing mutation, H874Y. Crystal structures of AR-LBD-H874Y bound to
testosterone and AR-20-30 FXXLF peptide indicated that the replacement of water-mediated
hydrogen bonds with direct hydrogen bonds between interior helices 4 and 5 and exterior
helix 10 increases androgen potency (Askew et al, 2007). AR-I737T was included as an AF2
site mutation that caused partial androgen insensitivity (He et al., 1999, 2006; Quigley et al.,
2004).
AR is stabilized in the presence of androgen by the androgen-dependent AR N/C interaction
(Kemppainen et al., 1992; He et al. 2001). AR stabilization determined on immunoblots
showed that the stability of wild-type AR and Y739A and I737T mutants increased in the
presence of DHT with or without the H874 mutation (Fig. 4A), whereas the stability of AR-
K905A increased only in the ARH874Y, K905A chimera. Transcriptional activity of AR-
Y739A, AR-K905A and AR-I737T was rescued by introducing the H874Y mutation (Fig.
4B). The results suggest that deleterious effects of AR-K905A, Y739A or I737T loss of
function mutations can be rescued by core helix stabilizing mutation H874Y that promotes
the AR N/C interaction and slows ligand dissociation.
3.5. NH2-terminal 23FQNLF27 flanking sequence contributes to the AR N/C interaction
Crystal structures of the AR LBD bound to testosterone and a short α-helical AR-20-30
FXXLF motif peptide suggested that Gln-902, Tyr-739 and Lys-905 lie in a region of the
LBD that interacts with residues NH2-terminal to the AR FXXLF motif (Fig. 3) (He et al.,
2004). In agreement with this, mammalian two-hybrid assays showed greater interaction of a
longer GAL-AR-2-30 FXXLF motif peptide with full-length wild-type AR and AR-I737T,
Y739A, Q902R and K905A mutants than the shorter GAL-AR-20-30 FXXLF motif peptide
(Fig. 5). Both GAL-AR peptides were expressed at similar levels in cells incubated with the
proteosome inhibitor MG132 to stabilize the peptides for detection on immunoblots (Fig. 5,
inset). However, the lack of electron density in the 2-19 amino acid region in the longer
AR-2-30 FXXLF motif peptide–AR LBD–testosterone crystal structure suggested that
interactions between residues NH2-terminal to the AR FXXLF motif and the carboxyl-
terminal extension of helix 12 were not sufficient to detect by crystallography.
4. Discussion
4.1. AR AF2 flanking residues influence FXXLF and LXXLL motif binding
Androgen-dependent transcriptional activity derives in part from the AR LBD AF2 region
that interacts with higher affinity with the AR NH2-terminal FXXLF motif (Askew et al.,
2007), and depends on p160 coactivator LXXLL motif binding. Studies in this report
identified a secondary interaction region structurally adjacent to the AF2 hydrophobic
binding cleft that facilitates FXXLF or LXXLL motif binding and retention of bound
hormone. Mutations in AR LBD helix 12 surface residues Lys-905 and helix 5 Tyr-739
disrupted FXXLF and LXXLL motif binding, even though equilibrium androgen binding
affinity was maintained similar to wild-type AR. Gln-902 in helix 12 was required for AR
FXXLF but not LXXLL motif binding. The slower dissociation rate of bound androgen from
the AR-Q902A LBD fragment suggested that prolonged androgen retention and high affinity
equilibrium androgen binding stabilizes the LBD core in a conformation that favors LXXLL
over FXXLF motif binding. The stabilizing effects of the prostate cancer somatic mutation
H874Y recovered AR transcriptional activity in the presence of loss of function
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destabilizing mutations. The studies suggest that AR LBD helix 12 Gln-902 outside the AF2
binding surface provides structural flexibility to accommodate binding of the FXXLF or
LXXLL motif.
Previous studies support a secondary interaction region near the AR LBD helix 12 extension
for AR FXXLF motif binding and AF2 function. The helix 12 L907F mutation outside the
AF2 cleft caused complete AIS and reduced AR FXXLF motif binding, even though high
affinity androgen binding was maintained (Jääskeläinen et al., 2006). Other AR LBD
mutations that cause AIS and disrupt AR FXXLF motif binding without altering equilibrium
androgen binding affinity include D695N prior to helix 3, R774H in helix 6, and R855H in
helix 10 (Jääskeläinen et al., 2006). Within the AF2 binding cleft, so called charge clamp
residues Lys-720 and Glu-897 differentiate FXXLF and LXXLL motif binding through the
formation of dissimilar hydrogen bonds. Crystal structures showed that bound FXXLF or
LXXLL peptides are phase shifted in the AF2 binding cleft. A hydrogen bond extends from
each peptide to Lys-720, whereas only the FXXLF motif also forms a hydrogen bond to
Glu-897 (He et al., 2002a, 2004, 2006; Dubbink et al., 2004). Thus, a K720A charge clamp
mutation disrupts LXXLL but not FXXLF motif binding most likely because the FXXLF
motif retains a hydrogen bond to Glu-897.
4.2. Detrimental effects of charged residue substitutions
Our studies highlight the potentially damaging effects of replacing nonpolar residues with
charged amino acids as seen with the naturally occurring arginine (Q902R), lysine (Q902K)
and aspartic acid (Y739D) substitution mutations that caused AIS or were associated with
prostate cancer. Q902R and Q902K disrupted FXXLF and LXXLL motif binding and
increased androgen dissociation even though equilibrium androgen binding affinity was
similar to wild-type AR. In contrast, the nonpolar Q902A alanine substitution slowed the
dissociation of DHT and R1881 and increased AR transcriptional activity. This suggests that
replacing nonpolar residues with charged residues may impose deleterious effects on
structure and function that do not necessarily reflect the true functional significance of the
native residue. Such an argument might be made for the G21E mutation that implicated a
role for Gly-21 in the AR N/C interaction (Callewaert et al., 2003). As suggested by our
studies, inhibition of the AR N/C interaction by the G21E charged residue substitution NH2-
terminal of the FXXLF motif may result in loss of function because of structural effects
imposed by the substituted charged residue. Similarly, Y739A was reported to retain high
affinity equilibrium androgen binding with rapid androgen dissociation kinetics, whereas
Y739D caused loss of androgen binding and complete AIS (Suzuki et al., 2001).
Evidence that residues NH2-terminal to the FXXLF motif interact with surface residues near
AR LBD helix 12 outside the AF2 binding cleft was suggested by the greater interaction of
the longer GAL-AR-2-30 FXXLF motif peptide with wild-type and mutant AR than the
shorter GAL-AR-20-30 FXXLF motif peptide. The findings are in agreement with earlier
studies that deletion of AR residues 3-13 from an AR-3-36 NH2-terminal fragment inhibited
the N/C interaction (Steketee et al., 2002). However, crystal structure of the extended
AR-2-30 FXXLF motif α-helical peptide bound–AR LBD–testosterone complex was
indistinguishable from that of the shorter AR-20-30 FXXLF motif peptide complex (He et
al., 2004). This suggests that sequence NH2-terminal to the FXXLF motif forms weak
interactions with the extended AR LBD helix 12 region that enhances AR transcriptional
activity by facilitating FXXLF or LXXLL motif binding to AF2.
4.3. Gain of function AR mutations in prostate cancer
One mechanism for prostate cancer progression is increased AR sensitivity to low levels of
androgen and increased levels of coactivators (Gregory et al., 2001a, b). However, some
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castration-recurrent prostate cancers have naturally occurring somatic mutations in or near
the AF2 site that maintain high affinity equilibrium androgen binding and transcriptional
activity. Activity-enhancing AR mutations may be selectively retained during prostate
cancer progression and castration-recurrent tumor growth. However, in contrast to the loss
of function Q902R mutation reported in prostate cancer (Taplin et al., 1995), AR-Q902A
had properties similar to the AR-H874Y somatic mutation identified in the CWR22
xenograft of human prostate cancer isolated from a hormone refractory bone marrow
metastasis of a patient treated with flutamide and LHRH agonist (Tan et al., 1997) and other
human prostate cancer specimens (Taplin et al., 1995). The H874Y mutation imparts DHT-
like activity to testosterone by stabilizing core helix interactions (He et al., 2006; Askew et
al., 2007; Lindström et al., 2010). Both ARQ902A and AR-H874Y more effectively retained
bound androgen independent of the N/C interaction. The ability of H874Y to overcome the
disrupting effects of destabilizing mutations in or near AR LBD helix 12 demonstrates that
compensatory structural changes can enhance AR transcriptional activity.
Conclusions
An extended region in and near AR LBD helix 12 outside the AF2 binding surface provides
weak interactions that discriminate AR FXXLF and coactivator LXXLL motif binding
required for AR transcriptional activity.
Abbreviations
AR androgen receptor
LBD ligand binding domain
AF2 activation function 2
N/C NH2- and carboxyl-terminal
TIF2 transcriptional intermediary factor 2
AIS androgen insensitivity syndrome.
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Figure 1. AR LBD helix 12 Gln-902 facilitates FXXLF motif binding to AF2
(A) HeLa cells were transfected with 0.1 µg 5XGAL4Luc, 0.05 µg GAL-AR-658-919 wild-
type (WT), Q902K, Q902R or Q902A mutant and 0.05 µg pNLVP16 empty vector, VP-
AR-1-660 or VP-TIF2-624-1287. Cells were incubated for 24 h in serum-free medium with
and without 10 nM DHT. (Inset) COS cells were transfected with 10 µg DNA/10 cm dish of
GALO empty vector (−),GAL-AR-658-919 WT, H874Y, Q902A, Q902R and Q902K
mutants. Cells were incubated with 1 µM MG132 for 24 and again at 1 h prior to harvest
and 50 µg protein/lane was probed using GAL and β-actin antibodies. (B) HeLa cells were
transfected with 0.1 µg 5XGAL4Luc3, 0.05 µg GAL-AR-658-919 WT, Q902A or H874Y
mutant and 0.05 µg pNLVP16 empty vector (VP16), VP-AR-1-660 or VP-TIF2-624-1287.
Cells were incubated for 24 h in serum-free medium with and without 0.01, 0.1, 1 and 10
nM DHT. (C) HeLa cells were transfected with 0.1 µg 5XGAL4Luc3, 0.05 µg GAL-
AR-658-919 WT, Y739A or K905A mutant, and 0.05 µg pNLVP16 empty vector (VP16),
VP-AR-1-660 or VP-TIF2-624-1287. Cells were incubated for 24 h in serum-free medium
with and without 0.1, 1 and 10 nM DHT.
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Figure 2. Modulation of AR transcriptional activity by LBD mutations flanking AF2
(A) COS cells were transfected with 5 µg pCMV5 empty vector (−), pCMV-AR wild-type
(WT) or the indicated mutant. Cell extracts (40 µg protein/lane) were probed using AR52
and β-actin antibodies. (B, C) CV1 cells were transfected with 5 µg PSA-Enh-Luc and 0.1
µg pCMV-AR WT, H874Y, Q902A, Q902R, Q902K, Y739A and K905A mutants analyzed
by immunoblot in (A). Cells were incubated for 48 h in serum-free medium with and
without 0.1, 1 and 10 nM DHT (B) or testosterone (T) (C).
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Figure 3. Superimposed surface representation of AR FXXLF and TIF2 LXXLL motif peptides
bound to AF2 in the AR LBD-testosterone complex
AR-20-30 FXXLF (orange) and TIF2-740-753 LXXLL (yellow/green) motif peptides contact
the AF2 surface flanked by AF2 helix 12 surface residues Glu-897 (AF2 E897, red) and
helix 3 Lys-720 (H3 K720, blue) within clusters of charged residues (He and Wilson, 2003;
He et al., 2004). NH2-terminal AR FXXLF motif residues 2-19 were predicted to extend
toward AR LBD surface residues helix 12 Gln-902 (H12 Q902), helix 5 Tyr-739 (H5 Y739)
and helix 12 Lys-905 (H12 K905).
Askew et al. Page 15













Figure 4. Functional rescue of destabilizing AR mutations by H874Y
(A) COS cells were transfected with 5 µg/10 cm dish of pCMV5 empty vector (−),pCMV-
AR wild-type (WT), H874Y, Y739A, H874Y/Y739A, K905A, H874Y/K905A, I737T or
H874Y/I737T mutants. Cells were incubated for 24 h with and without 10 nM DHT. The
transblot containing 40 µg cell extract protein/lane was probed using AR32 and β -actin
antibodies. (B) HeLa cells were transfected with 0.25 µg PSA-Enh-Luc and 0.01 µg WT
pCMV-AR or mutants in (A). Cells were incubated for 24 h in serum-free medium with and
without 0.1 and 1 nM testosterone (T).
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Figure 5. Amino acid residues NH2-terminal to the AR FXXLF motif enhance the AR N/C
interaction
HeLa cells were transfected with 0.1 µg 5XGAL4Luc3, 2 ng wild-type (WT) pCMV-AR,
I737T, Y739A, Q902R or K905A mutant, and 0.05 µg GAL-AR-2-30 or GAL-AR-20-30
FXXLF motif peptides. Cells were incubated in serum-free medium for 24 h with and
without 0.1 nM testosterone (T) or DHT (D). (Inset) COS cells were transfected with 10 µg
GALO empty vector (−), GAL-AR-2-30 or GAL-AR-20-30 FXXLF motif peptides. Cells
were treated with 1 µM MG132 for 24 h and again at 1 h prior to harvest. The transblot was
probed using GAL and β-actin antibodies.
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